Evidence map›Paper›PMID 33281451›Full record

ArticleBreast cancer : basic and clinical research2020

Pleomorphic Invasive Lobular Carcinoma of the Breast With Extracellular Mucin and

Matthew J Burky, Emily M Ray, David W Ollila, Siobhan M O'Connor, Johann D Hertel, Benjamin C Calhoun

Open access · goldAbstract readCase Reports
In one paragraph

Article in Breast cancer : basic and clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Matthew J BurkyAnatomic Pathology, Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.
Emily M RayDivision of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
David W OllilaLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Siobhan M O'ConnorAnatomic Pathology, Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.
Johann D HertelAnatomic Pathology, Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.
Benjamin C CalhounAnatomic Pathology, Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.ORCID https://orcid.org/0000-0001-6505-5430
University of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive lobular carcinoma with extracellular mucin is an uncommon pattern of invasive breast carcinoma. The 5th Edition of the World Health Organization Classification of Breast Tumors states that it is unknown whether these tumors are a subtype of mucinous carcinoma or invasive lobular carcinoma. Invasive lobular carcinoma with extracellular mucin frequently presents as a palpable mass and may be more likely to be grade 2 to 3 and HER2-positive than classic invasive lobular carcinoma. This case of pleomorphic invasive lobular carcinoma with extracellular mucin was detected by imaging only and was HER2-amplified, suggesting that a subset of these tumors may be clinically occult with an aggressive phenotype. Invasive lobular carcinoma with extracellular mucin is infrequently encountered and awareness of this entity is helpful in avoiding misdiagnosis.

Indexed as

breastdiagnosisHER2invasivelobularpathologyPleomorphicsurgery

Identifiers

PMID33281451
PMCPMC7691944
OpenAlexW3108968478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.